These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11453075)

  • 1. How should hyperuricemia be treated in a patient with allopurinol hypersensitivity?
    Monev SD
    Cleve Clin J Med; 2001 Jul; 68(7):597-8. PubMed ID: 11453075
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral desensitization in patients with chronic tophaceous gout and allopurinol hypersensitivity.
    Gillott TJ; Whallett A; Zaphiropoulos G
    Rheumatology (Oxford); 1999 Jan; 38(1):85-6. PubMed ID: 10334688
    [No Abstract]   [Full Text] [Related]  

  • 3. Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient.
    Fam AG
    Curr Rheumatol Rep; 2001 Feb; 3(1):29-35. PubMed ID: 11177768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful desensitization of a fixed drug eruption caused by allopurinol.
    Umpiérrez A; Cuesta-Herranz J; De Las Heras M; Lluch-Bernal M; Figueredo E; Sastre J
    J Allergy Clin Immunol; 1998 Feb; 101(2 Pt 1):286-7. PubMed ID: 9500766
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of asymptomatic hyperuricemia].
    Floege J
    Internist (Berl); 1997 Dec; 38(12):1233. PubMed ID: 9465329
    [No Abstract]   [Full Text] [Related]  

  • 6. [De-sensitization to allopurinol in a patient with tophi gout].
    López-Rocha EG; Hernández-Montoya G; Rodríguez-Pesina AH; Rodríguez-Mireles KA
    Rev Alerg Mex; 2018; 65(3):316-320. PubMed ID: 30176211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [How to treat hyperuricemia and gout attacks in compensated kidney failure?].
    Gröbner W
    Dtsch Med Wochenschr; 2002 Mar; 127(11):576. PubMed ID: 11894180
    [No Abstract]   [Full Text] [Related]  

  • 8. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On call. I've had gout for many years. I used to take Zyloprim without any problems, but I just had a severe allergic reaction, so my doctor switched me to Benemid. I'm doing okay, but the drug sometimes upsets my stomach. Do you have any suggestions?
    Simon HB
    Harv Mens Health Watch; 2010 Jan; 14(6):7-8. PubMed ID: 20464796
    [No Abstract]   [Full Text] [Related]  

  • 10. [Hyperuricemia and gout: therapeutic indications].
    Pawlotsky Y
    Rev Prat; 1994 Jan; 44(2):206-9. PubMed ID: 8178077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lesinurad/allopurinol (Duzallo) for gout-associated hyperuricemia.
    Med Lett Drugs Ther; 2017 Nov; 59(1533):182-183. PubMed ID: 29125593
    [No Abstract]   [Full Text] [Related]  

  • 13. [Hyperuricemia and gout--treatment].
    Gröbner W; Walter-Sack I
    Dtsch Med Wochenschr; 2002 Feb; 127(5):210-3. PubMed ID: 11821994
    [No Abstract]   [Full Text] [Related]  

  • 14. Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia.
    Gutiérrez-Macías A; Lizarralde-Palacios E; Martínez-Odriozola P; Miguel-De la Villa F
    BMJ; 2005 Sep; 331(7517):623-4. PubMed ID: 16166134
    [No Abstract]   [Full Text] [Related]  

  • 15. Allopurinol hypersensitivity reactions: desensitization strategies and new therapeutic alternative molecules.
    Calogiuri G; Nettis E; Di Leo E; Foti C; Ferrannini A; Butani L
    Inflamm Allergy Drug Targets; 2013 Feb; 12(1):19-28. PubMed ID: 23092365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allopurinol hypersensitivity in a patient with severe, chronic, tophaceous gout.
    Webster E; Panush RS
    Arthritis Rheum; 1985 Jun; 28(6):707-9. PubMed ID: 4004980
    [No Abstract]   [Full Text] [Related]  

  • 17. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
    Dalbeth N; Kumar S; Stamp L; Gow P
    J Rheumatol; 2006 Aug; 33(8):1646-50. PubMed ID: 16783857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allopurinol: insights from studies of dose-response relationships.
    Day RO; Kannangara DR; Stocker SL; Carland JE; Williams KM; Graham GG
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):449-462. PubMed ID: 27927043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperuricemia and gout.
    Sloan RW
    J Fam Pract; 1982 May; 14(5):923-6, 930-1, 934. PubMed ID: 7042900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperuricemia and gout: a reign of complacency.
    Mandell BF
    Cleve Clin J Med; 2002 Aug; 69(8):589-90, 592-3. PubMed ID: 12184467
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.